Increasing Prevalence of Hydrocephalus to Drive Global Hydrocephalus Shunts Market

According to our new market research study, titled ""Hydrocephalus Shunts Market to 2028 - Global Analysis and Forecast - by Product, Type, Age Group, and End User,"" the market is expected to grow from US$ 286.19 million in 2021 to US$ 360.01million by 2028; it is estimated to grow at a CAGR of 3.4% from 2022 to 2028. The report highlights trends prevailing in the market, and drivers and restraints pertaining to the hydrocephalus shunts market.

Shunt, the surgical insertion of a drainage system, is the most common remedy for hydrocephalus. It drains extra cerebrospinal fluid from the brain and directs it to another body part, such as the abdomen, where it can be more easily absorbed. A shunt consists of a long and flexible tube with a valve that keeps fluid from the brain flowing in the right direction, at the proper rate.

Companies in the hydrocephalus shunts market are introducing new advanced programmable valves, shunts based on the latest technologies, and anti-siphon devices, among others. In May 2021, researchers at the Pennsylvania State University established the startup named Cranial Devices Inc. HydroFix, an advanced surgical shunt system designed by this company, provides a durable solution for normal pressure hydrocephalus (NPH) patients, along with mitigating risks associated with currently existing shunts. They have also applied for a license for the HydroFix technology from the Pennsylvania State University. In 2020, researchers at MIT proposed a shunt design to overcome the clogging of hydrocephalus catheters by leveraging catheter geometry.

North America holds the largest market share of the hydrocephalus shunts market, whereas Asia Pacific is expected to register the highest CAGR during the forecast period. The hydrocephalus shunts market in the US is expected to grow from US$ 105.98 million in 2021 to US$ 135.48 million by 2028; it is expected to grow at a CAGR of 3.6% during the forecast period. Hydrocephalus is a prime cause of morbidity worldwide, and it is estimated to affect ~1 million people in the US, with an approximate incidence of 0.2-0.8 per 1000 live births. According to the National Institute of Neurological Disorders and Stroke (NINDS), hydrocephalus is assumed to affect ~1-2 in every 1,000 children born in the US.

During the COVID-19 pandemic, there was a slight impact on the hydrocephalus shunts market performance due to delays in surgeries. Agencies such as the Hydrocephalus Association maintain that hydrocephalus has not itself been identified as a risk factor for contracting COVID-19, many patients have had their surgeries postponed indefinitely and their follow-up appointments cancelled or moved to virtual platforms. Hydrocephalus treatment (shunt or ETV) does not increase a person’s risk for contracting COVID‑19 or developing severe COVID-19 disease.

B. Braun Melsungen AG (CHRISTOPH MIETHKE GMBH & CO. KG); Sophysa; HpBio Próteses, inc.; Integra LifeSciences Holdings Corporation; KANEKA MEDIX CORP.; Medtronic; Natus Medical Incorporated; Spiegelberg GmbH & Co. KG; and Desu Medical are the leading companies in the hydrocephalus shunts market.

On the basis of geography, the hydrocephalus shunts market is segmented into North America (US, Canada, and Mexico), Europe (UK, Germany, France, Italy, Spain, and Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia Pacific), the Middle East & Africa (UAE, Saudi Arabia, Africa, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South and Central America).

Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id:sales@premiummarketinsights.com